GLUB5 Antibody

What is GLUT5 and why is it significant in metabolic research?

GLUT5 (SLC2A5) is a 501-amino acid facilitative glucose transporter protein, primarily functioning as a fructose transporter that exhibits low activity with other monosaccharides . It belongs to the Major facilitator superfamily and the Sugar transporter family (TC 2.A.1.1) . GLUT5 is predominantly expressed in the small intestine and at lower levels in kidney, testis, skeletal muscle, and adipose tissue, where it plays a critical role in fructose absorption . The protein is membrane-associated and contains glycosylation sites that affect its function . GLUT5's importance extends beyond basic nutrient transport, as it participates in physiological processes like intestinal absorption and has been implicated in various pathological conditions, making it a valuable target for antibody-based research applications .

What are the main types of GLUT5 antibodies available for research applications?

Research-grade GLUT5 antibodies are available in multiple formats including monoclonal and polyclonal variants with various species reactivity profiles. Monoclonal antibodies such as the clone #195205 (mouse IgG2A) offer high specificity for human GLUT5 and are optimized for applications like flow cytometry . Polyclonal antibodies, like rabbit anti-GLUT5 variants, generally provide broader epitope recognition and are suitable for applications including Western blot, immunohistochemistry (IHC), and immunofluorescence (IF) . These antibodies are available in conjugated forms (including Alexa Fluor® 647, HRP, FITC, and PE conjugates) for direct detection applications, as well as unconjugated formats that require secondary antibody detection systems . Selection between monoclonal and polyclonal antibodies should be guided by the specific experimental requirements, with monoclonals typically providing higher specificity for single epitopes while polyclonals offer enhanced signal through multi-epitope binding.

How is GLUT5 protein structure related to antibody epitope selection?

GLUT5 contains 12 membrane-spanning domains with intracellular NH₂ and COOH termini, an N-linked glycosylation site, and conserved "sugar transporter signature" motifs . When selecting antibodies, researchers should consider the accessibility of epitopes based on this structural organization. Many commercial antibodies target epitopes in the C-terminal intracellular domain (e.g., amino acid residues 477-490 of rat GLUT5) or within the human SLC2A5 450-500 amino acid region . These regions are generally accessible in applications where the protein is denatured (Western blot) or in fixed and permeabilized samples (IHC). For applications requiring detection of native, non-denatured GLUT5 (like flow cytometry of living cells), antibodies recognizing extracellular epitopes are preferred. Understanding the relationship between GLUT5 structure and epitope accessibility is critical for selecting appropriate antibodies for specific experimental applications.

What validation steps should be performed when using GLUT5 antibodies in new experimental systems?

Comprehensive validation of GLUT5 antibodies requires multiple complementary approaches to ensure specificity and suitability for the intended application. First, researchers should examine species cross-reactivity data, as many GLUT5 antibodies demonstrate reactivity with human, mouse, and rat samples, though performance may vary across species . Western blot validation should include positive control samples with known GLUT5 expression (e.g., small intestine lysates, Caco-2 cells) alongside negative controls . Blocking peptide experiments, where the antibody is pre-incubated with the immunizing peptide before application, can confirm binding specificity by demonstrating signal abrogation . For flow cytometry, comparison of GLUT5-transfected cells with non-transfected controls provides robust validation of specificity . Additionally, knockdown or knockout validation, though not always commercially available, represents the gold standard for antibody validation. Researchers should also verify antibody performance in their specific application by testing dilution series to optimize signal-to-noise ratio.

How should GLUT5 antibodies be optimized for Western blot applications?

Optimizing GLUT5 antibody usage for Western blot requires careful attention to several technical parameters. The observed molecular weight of GLUT5 typically ranges from 48-70 kDa due to post-translational modifications, particularly glycosylation . Sample preparation is critical - using RIPA buffer has been verified for preparing both brain extracts and K562 lysates for GLUT5 detection . Recommended dilutions for GLUT5 antibodies in Western blots generally range from 1:200 to 1:2000, depending on the specific antibody and sample type . For example, Anti-GLUT5 (SLC2A5) Antibody #AGT-025 is recommended at 1:400 for mouse and rat brain membranes, but 1:200 for rat small intestine lysate . Positive control recommendations include Caco-2 cells, A549 cells, mouse kidney tissue, and rat testis tissue . When troubleshooting, consider that glycosylation heterogeneity may result in diffuse bands, and deglycosylation treatments may be necessary to obtain sharper bands. Furthermore, membrane protein extraction methods significantly impact the quality of GLUT5 detection, with special attention needed for proper solubilization of membrane proteins.

What are the critical parameters for successful immunohistochemistry with GLUT5 antibodies?

Successful immunohistochemical detection of GLUT5 requires optimization of several key parameters. Antigen retrieval methods significantly impact staining quality, with both citrate buffer (pH 6.0) and Tris-EDTA buffer (pH 9.0) being recommended depending on the specific antibody and tissue type . For paraffin-embedded sections, complete deparaffinization and appropriate permeabilization are essential for accessing membrane-associated epitopes. Blocking conditions typically employ 5% serum (e.g., horse serum) for 15-20 minutes to minimize non-specific binding . Antibody concentration and incubation conditions vary by product, but dilutions between 1:50 and 1:500 are common, with overnight incubation at 4°C often yielding optimal results . Detection systems may include fluorescent secondary antibodies (e.g., AlexaFluor-488 conjugates) for fluorescence microscopy or HRP-conjugated systems for chromogenic detection . GLUT5 expression patterns show tissue specificity - in brain tissue, GLUT5 staining appears in the pyramidal layer of the hippocampal CA3 region and in Purkinje cells of the cerebellum . For cancer tissues, GLUT5 antibodies have been validated on human breast and lung cancer specimens . Researchers should include appropriate positive controls (small intestine) and negative controls (antibody omission or isotype controls) in all IHC experiments.

How can GLUT5 antibodies be utilized in flow cytometry applications?

Flow cytometry with GLUT5 antibodies requires specific technical considerations for optimal results. Using directly conjugated antibodies, such as the Human GLUT5 Alexa Fluor® 647-conjugated Antibody, can simplify protocols by eliminating the need for secondary antibody incubation steps . When using unconjugated primary antibodies, phycoerythrin-conjugated secondary antibodies have been successfully employed . For best results, cell preparation should preserve membrane integrity, with gentle dissociation methods preferred over harsh enzymatic treatments that might degrade surface proteins. Controls should include both unstained cells and isotype controls to establish background fluorescence levels. Validation experiments have successfully employed GLUT5-transfected NS0 mouse myeloma cells compared against irrelevant transfectants as a specificity control . This approach provides clear discrimination between positive and negative populations. Recommended antibody concentrations may vary, but protocols typically use 10 μg/mL final concentration with 30-60 minute incubation periods at 4°C to minimize internalization. For multicolor flow cytometry, careful panel design is essential to avoid spectral overlap with other fluorophores, particularly when using PE or APC fluorophores that may overlap with Alexa Fluor® 647 signals.

What strategies can address common specificity concerns with GLUT5 antibodies?

Addressing specificity concerns with GLUT5 antibodies requires a comprehensive validation strategy. Peptide competition assays, where the antibody is pre-incubated with the immunizing peptide (such as GLUT5/SLC2A5 Blocking Peptide), should demonstrate significant or complete signal abrogation in the blocked sample compared to the unblocked control . Experimental models with variable GLUT5 expression can provide additional validation - comparing tissues or cell lines with known high expression (small intestine, Caco-2 cells) against those with low or no expression . Cross-reactivity with other GLUT family members is a potential concern given sequence homology; researchers should examine antibody datasheets for cross-reactivity testing data against related proteins like GLUT1-4. For definitive validation, modern approaches include using CRISPR/Cas9 knockout cell lines or siRNA knockdown models to confirm signal loss when the target is absent. Additionally, orthogonal detection methods (using antibodies targeting different epitopes) should produce consistent results across multiple detection platforms. Western blot analysis with careful molecular weight assessment can help distinguish between specific GLUT5 signal (48-70 kDa depending on glycosylation) and potential cross-reactive proteins.

How can strategic glycan engineering enhance GLUT5 antibody performance?

Strategic glycan engineering represents an advanced approach to enhancing antibody performance against targets like GLUT5. Research demonstrates that the placement of N-linked glycans in the variable region of monoclonal antibodies can substantially enhance activity and alter binding characteristics . This approach has been successfully employed to improve antibody binding to targets that have mutations affecting glycosylation patterns. For example, one study showed that engineering an N-linked glycan into an antibody light chain at a position spatially proximal to a target's variable region restored susceptibility to the antibody for variants that had lost their natural glycosylation . This "refilling" approach compensated for the void created by glycan loss in the target protein. Applied to GLUT5 research, this could be particularly relevant since GLUT5 contains glycosylation sites that affect its structure and function . For researchers developing custom antibodies against GLUT5, strategic glycan placement in the antibody's complementarity-determining regions (CDRs) could potentially enhance binding specificity or affinity, particularly when targeting glycosylated epitopes of GLUT5. This approach requires advanced molecular engineering techniques but offers potential solutions for difficult detection scenarios or for developing therapeutic antibodies with enhanced properties.

How are computational methods advancing antibody design for targets like GLUT5?

Computational antibody design represents a cutting-edge approach that can be applied to develop highly specific antibodies against GLUT5. Recent advances demonstrate that precise, sensitive, and specific antibody design can be achieved without prior antibody information through computational methods based on atomic-accuracy structure prediction . These methods have successfully generated antibodies for multiple target proteins by creating libraries combining designed light and heavy chain sequences. For GLUT5 research, computational design could potentially address challenges in discriminating between closely related glucose transporter family members. The approach involves several sophisticated steps: first, structural modeling of the GLUT5 protein using tools like AlphaFold; second, identification of unique, accessible epitopes distinguishing GLUT5 from other GLUT family members; third, in silico design of complementarity-determining regions (CDRs) optimized for these epitopes; and finally, virtual screening to predict binding affinities . This computational pre-screening can substantially reduce the experimental library size needed, making the antibody development process more efficient. The method has demonstrated the ability to achieve high molecular specificity, with designed antibodies capable of distinguishing closely related protein subtypes or mutants - a crucial consideration for GLUT5 research where specificity against other glucose transporters is essential .

What are the key considerations when selecting between phage display and hybridoma methods for GLUT5 antibody generation?

The choice between phage display and hybridoma technologies for generating GLUT5 antibodies involves weighing several technical considerations. Hybridoma technology, a traditional approach, involves immunizing animals (typically mice or rats) with GLUT5 protein or peptides, extracting B cells from the spleen, and fusing them with immortal myeloma cells . This approach generates monoclonal antibodies that have undergone in vivo affinity maturation, often resulting in high-affinity binders . Key considerations include the time requirement (typically 3-6 months), the need for animal immunization, and the limitation to antibodies from the immunized species' repertoire . Modern hybridoma protocols have improved efficiency through advanced cloning supplements like MilliporeSigma's BM Condimed H1, which eliminates the need for feeder layers or animal serums .

For GLUT5 research, hybridoma methods may be preferred when developing antibodies against complex conformational epitopes of the native protein, while phage display offers advantages when targeting specific known sequences or when high specificity against related GLUT family members is required .

How can single B cell screening technologies enhance GLUT5 antibody discovery?

Single B cell screening technologies represent an advanced approach to antibody discovery that can significantly accelerate the development of high-quality GLUT5 antibodies. This methodology circumvents the time-consuming process of generating and testing hybridomas by directly isolating and characterizing antibody-producing B cells . The process involves several sophisticated steps: first, animals are immunized with GLUT5 protein or peptides; second, individual B cells are isolated from immunized animals; third, cells undergo lysis for extraction of genetic material; fourth, antibody heavy and light chain variable-region genes are sequenced; and finally, these sequences are cloned into expression vectors for recombinant antibody production . The primary advantage of this approach is the ability to rapidly screen thousands of individual B cells to identify those producing antibodies with desired characteristics, such as high affinity or specificity for particular GLUT5 epitopes. Additionally, the method preserves the natural heavy and light chain pairing of each B cell, potentially yielding antibodies with superior binding properties compared to randomly paired libraries. For GLUT5 research, this approach could be particularly valuable when searching for antibodies that can distinguish between closely related glucose transporter family members or when targeting specific conformational epitopes. Implementation requires specialized equipment for single-cell isolation and handling (such as fluorescence-activated cell sorting or microfluidic systems), but offers substantial time savings compared to traditional hybridoma methods.

What are common challenges in detecting GLUT5 in tissue samples and how can they be addressed?

Detection of GLUT5 in tissue samples presents several technical challenges that require specific troubleshooting approaches. First, membrane protein extraction efficiency significantly impacts GLUT5 detection, as the protein's membrane-associated nature can make it difficult to solubilize completely . Using optimized membrane protein extraction buffers containing appropriate detergents (such as RIPA buffer) improves recovery . Second, fixation methods critically affect epitope preservation - for immunohistochemistry, 10% buffered formalin fixation followed by antigen retrieval is recommended, with microwave heating in either pH 6 citrate buffer or pH 9 Tris-EDTA buffer depending on the specific antibody . Third, glycosylation heterogeneity may result in diffuse or multiple bands on Western blots; deglycosylation treatments can be employed to obtain sharper bands when necessary. Fourth, endogenous peroxidase activity in tissues like liver or kidney can produce false-positive signals in HRP-based detection systems; this can be mitigated with hydrogen peroxide blocking steps (typically 0.3-3% H₂O₂ for 10-30 minutes). Fifth, GLUT5's expression level varies significantly between tissues - highest in small intestine with lower levels in kidney, testis, skeletal muscle, and adipose tissue - requiring optimization of antibody concentration for each tissue type. Finally, background staining can be minimized through optimized blocking procedures (5% serum or BSA solutions) and by testing multiple antibody dilutions to determine the optimal signal-to-noise ratio .

How can researchers troubleshoot inconsistent results in flow cytometry with GLUT5 antibodies?

Inconsistent flow cytometry results with GLUT5 antibodies can stem from multiple sources that require systematic troubleshooting. Cell preparation techniques significantly impact results - membrane proteins like GLUT5 are sensitive to harsh enzymatic dissociation methods, which can cleave or alter surface epitopes . Using gentler non-enzymatic dissociation reagents or short exposure times with dilute enzymatic solutions can preserve the integrity of surface antigens. Antibody titration is essential, as both insufficient and excessive concentrations lead to poor discrimination between positive and negative populations; a titration series (typically 0.1-10 μg/mL) should be tested to determine optimal concentration. Fixation can affect epitope accessibility - if fixation is necessary, comparing different fixatives (paraformaldehyde versus alcohol-based) and concentrations (0.5-4%) can identify optimal conditions. Permeabilization should generally be avoided for surface GLUT5 detection but may be necessary for intracellular epitopes. For multi-color panels, compensation settings must be properly established to avoid false positives from spectral overlap, particularly with fluorophores like PE and Alexa Fluor® 647 that have broad emission spectra . Controls should include not only unstained cells but also fluorescence-minus-one (FMO) controls and isotype controls matched to the primary antibody's isotype, concentration, and fluorophore. Additionally, confirming GLUT5 expression levels in the cell population through orthogonal methods (qPCR, Western blot) can help interpret flow cytometry results, especially with cell types where expression might be variable or regulated by culture conditions.

What considerations apply when using GLUT5 antibodies for immunoprecipitation studies?

Immunoprecipitation (IP) with GLUT5 antibodies requires careful optimization to achieve successful results. The choice of lysis buffer significantly impacts IP efficiency for membrane proteins like GLUT5 - buffers containing appropriate detergents (such as RIPA or NP-40-based buffers) effectively solubilize membrane proteins while preserving antibody-epitope interactions . Pre-clearing lysates with Protein A/G beads before adding the antibody removes components that bind non-specifically to the beads, reducing background. Antibody amount requires optimization - excess antibody may increase non-specific binding while insufficient antibody reduces yield; titration experiments with 1-10 μg antibody per 100-500 μg total protein are recommended. Incubation conditions affect binding efficiency - overnight incubation at 4°C with gentle rotation typically yields optimal results . The washing stringency balance is critical - insufficient washing results in high background, while excessive washing reduces specific yield; typically, 3-5 washes with decreasing detergent concentrations provide a good balance. For GLUT5 detection after IP, Western blot analysis should employ antibodies recognizing different epitopes than those used for IP to confirm specificity . Successful IP has been demonstrated with rRBD and antibodies like CU-28-24, with specific detection of the immunoprecipitated protein by immunoblotting using labeled detection antibodies . When troubleshooting failed IP experiments, consider that certain epitopes may be inaccessible in the native protein conformation or that the antibody's affinity may be insufficient for IP applications despite working in other applications like Western blotting.